7 | POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA‐R‐GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): PHASE III POLARGO TRIAL

Documenti analoghi

• 76 | GLOFITAMAB PLUS GEMCITABINE AND OXALIPLATIN (Glofit‐GemOx) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL): 2‐YEAR FOLLOW‐UP OF STARGLO
  di: J. S. Abramson, et al.
  Pubblicazione: (2025)
• 285 | EFFICACY AND SAFETY OF POLATUZUMAB VEDOTIN, ZANUBRUTINIB AND RITUXIMAB IN UNTREATED ELDERLY AND FRAIL DLBCL PATIENTS: A PROSPECTIVE PHASE 2 CLINICAL TRIAL
  di: Y. Ren, et al.
  Pubblicazione: (2025)
• 282 | DURABLE EFFICACY WITH FIXED‐DURATION EPCORITAMAB + POLATUZUMAB, VEDOTIN, RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA‐R‐CHP) FOR 1L DLBCL (EPCORE NHL‐5)
  di: D. Lavie, et al.
  Pubblicazione: (2025)
• LBA3 | MOSUNETUZUMAB PLUS POLATUZUMAB VEDOTIN IS SUPERIOR TO R‐GemOx IN TRANSPLANT‐INELIGIBLE PATIENTS WITH R/R LBCL: PRIMARY RESULTS OF THE PHASE III SUNMO TRIAL
  di: J. Westin, et al.
  Pubblicazione: (2025)
• LBA1 | THE BENEFIT OF POLA‐R‐CHP IN DLBclass‐DEFINED MOLECULAR SUBSETS OF NEWLY DIAGNOSED DLBCL IN THE POLARIX TRIAL
  di: E. Calabretta, et al.
  Pubblicazione: (2025)